# Local manufacturing for market access Contract development, technology-transfer and local-build services that establish in-country or regional biomanufacturing so a biologic or vaccine qualifies for market access, procurement preference and supply security in target jurisdictions. Source: https://en.bioecon.ru/technology/local-manufacturing-for-market-access/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: FDA cGMP / EU GMP | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] Local manufacturing for market access is the service of establishing biopharmaceutical production inside a target country or region so that a product qualifies for market entry, government procurement preference and supply security, typically through a CDMO, technology transfer or a joint local-build. It is surging because governments are treating domestic drug supply as strategic: Thermo Fisher flags 500 billion US dollars of announced US biomanufacturing investments by big pharma as a structural tailwind and is itself executing a 1 billion US dollar CDMO investment plan. CDMOs with a global footprint convert that demand into capacity, with Lonza citing its available US capacity and global network as a core competitive advantage and WuXi Biologics running roughly 580,000 litres of installed biologic capacity across a network that now extends to Singapore and Qatar. For emerging markets, local manufacturing is also a market-access condition: Biocon Biologics earned EMA approval of a new monoclonal-antibody facility in India alongside GMP renewals for its India and Malaysia sites, turning local build into EU market access. The key directions of local manufacturing for market access are: 1. **Contract development and manufacturing (CDMO services):** outsourcing local production to a global CDMO (Catalent, Lonza, Thermo Fisher Patheon) with an existing GMP site in the target market. 2. **Technology transfer (Process transfer):** transferring a validated process from an originator to a local manufacturer under GMP, including analytical comparability. 3. **Modular local build (Modular biomanufacturing):** deploying pre-fabricated, modular biologics plants (WuXi Biologics Singapore) to compress time-to-capacity. 4. **Multi-site GMP network qualification (Network access):** qualifying a network of GMP sites across jurisdictions so one product can be supplied to many markets from different origins. ### Sectoral value chain ``` [Market-access & site decision] ──> [CDMO selection / local partner] ──> [Technology transfer] ──> [GMP build & qualification] │ (Regulatory filing) │ ▼ [Commercial supply] <─── [Inspection & approval] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Market-access decision** | Defining the target market, local-content rules and the make-vs-partner strategy. | **In:** Market, demand.
**Out:** Access plan. | | **CDMO / local partner selection** | Choosing a CDMO with a qualifying site or a local manufacturing partner. | **In:** Access plan.
**Out:** Partner/site. | | **Technology transfer** | Moving the validated process, cell line and analytics to the chosen site. | **In:** Originator process.
**Out:** Transferred process. | | **GMP build & qualification** | Building or fitting out the local line and qualifying it (IQ/OQ/PQ). | **In:** Transferred process.
**Out:** Qualified line. | | **Inspection & approval** | FDA, EMA or NMPA inspection and market authorisation of the local site. | **In:** Qualified line.
**Out:** Site approval. | | **Commercial supply** | Producing and supplying product for the target market under the access agreement. | **In:** Site approval.
**Out:** Marketed product. | Cross-cutting technologies of the sector: - **CDMO multi-site networks:** global GMP capacity (Lonza Visp/US, Catalent, Thermo Fisher Patheon) that lets a sponsor manufacture in-region without owning a plant. - **Modular biomanufacturing:** pre-fabricated biologics modules (WuXi Biologics Singapore) that cut construction and commissioning time. - **Technology transfer toolkits:** standardised process, analytical and comparability packages that move a product between sites with minimal revalidation. --- ## US The United States is the centre of the local-manufacturing-for-access build-out, with hundreds of billions of announced biomanufacturing investment and the largest CDMO networks. ### Reshoring wave, big CDMO investment, US capacity advantage - **Investment tailwind:** Thermo Fisher (originating 1956) sees 500 billion US dollars of announced US biomanufacturing investment by big pharma as a tailwind and is executing a 1 billion US dollar CDMO investment plan of its own. - **Reshoring partnerships:** Catalent (founded 1957) supports reshoring of US pharmaceutical manufacturing in 2026 and pairs US capacity with late-phase specialist partnerships such as its AAV alliance with Elpida. - **Capacity as advantage:** Lonza cites its available US capacity and global footprint as a major competitive advantage in capturing the access-driven build-out. --- ## CN China combines the largest biologics CRDMO with an aggressive global footprint expansion that turns domestic capacity into worldwide market access. ### CRDMO scale, global network, modular builds - **Capacity leader:** WuXi Biologics (founded 2010) runs roughly 580,000 litres of installed biologic capacity and has won the CDMO Leadership Award for nine consecutive years. - **Global modular expansion:** WuXi Biologics topped out a modular biologics CRDMO plant in Singapore and signed a strategic memorandum with the Qatar Free Zone Authority, extending its access-enabling network. - **Standards recognition:** inclusion in the 2026 Dow Jones Sustainability World Index reinforces WuXi Biologics' qualification as a multi-jurisdiction manufacturing partner. --- ## EU Europe anchors the heritage CDMO industry and the large-scale mammalian capacity that underpins both EU access and exports. ### Pure-play CDMO, large-scale mammalian, footprint focus - **Pure-play CDMO:** Lonza (founded 1897, Switzerland) is completing its transformation into a pure-play CDMO and continues ramping its large-scale mammalian site in Visp, with an India hub adding fermentation leadership. - **Sterile and OSD investment:** Recipharm (founded 1995, Sweden) is investing multi-million sums in US sterile manufacturing, a new BFS line and high-potency OSD at Leganés, sharpening its access-enabling footprint. - **Footprint focus:** Recipharm is actively reshaping its network, divesting an Israel API plant to form a CDMO alliance with Scinai, illustrating how CDMOs reconfigure sites to serve access strategies. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Catalent** | 🇺🇸 USA | *CDMO + late-phase partnerships* | AAV / iPSC manufacturing | commercial | | **Lonza** | 🇨🇭 Switzerland | *Pure-play CDMO* | Visp large-scale mammalian | commercial | | **Recipharm** | 🇸🇪 Sweden | *Sterile + OSD CDMO* | BFS + high-potency OSD | commercial | | **Thermo Fisher** | 🇺🇸 USA | *Patheon CDMO network* | $1B CDMO investment plan | commercial | | **WuXi Biologics** | 🇨🇳 China | *Global CRDMO* | 580,000 L biologic capacity | commercial | | **Biocon** | 🇮🇳 India | *Biosimilars + local build* | EMA-approved India mAbs site | commercial | --- ## Tech stack and innovations The local-manufacturing stack is built on multi-site CDMO networks, modular plant design and disciplined technology transfer that make in-region capacity faster and cheaper than greenfield ownership. 1. **CDMO multi-site GMP networks:** - Networks of qualified GMP sites across regions let a sponsor manufacture in-region without owning a plant, satisfying local-content and supply-security rules. - Thermo Fisher's Patheon network and Catalent's global sites convert the 500-billion-US-dollar US investment wave into immediately bookable capacity. 2. **Modular biomanufacturing:** - Pre-fabricated biologics modules ship as skid-mounted units and commission in months rather than years, the model WuXi Biologics is deploying in Singapore. - Modular lines pair naturally with single-use bioreactors, shortening both build and changeover for multi-product access supply. 3. **Technology-transfer toolkits:** - Standardised process, analytical and comparability packages move a product between sites with minimal revalidation, the engineering step that makes local manufacturing viable. - Catalent's Qai quality-assurance platform exemplifies the digital tooling now wrapping technology transfer to shorten the path from transfer to approved supply. --- ## Value chains and production pipelines ### Industrial pipeline of a local-manufacturing-for-access project (FDA cGMP / EU GMP) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Access & site decision │ ───> │ 2. CDMO / partner select │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. GMP build & qualify │ <─── │ 3. Technology transfer │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Inspection & approval │ ───> │ 6. Commercial supply │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Access and site decision The sponsor maps the target market, its local-content and procurement rules, and the make-vs-partner trade-off, producing an access plan that defines where production must physically sit. #### Stage 2: CDMO or partner selection The sponsor selects a CDMO with a qualifying GMP site (Catalent, Lonza, Thermo Fisher Patheon) or a local manufacturer, evaluating available capacity, technology fit and regulatory track record. #### Stage 3: Technology transfer The validated process, cell line and analytical methods are transferred to the chosen site, with comparability studies demonstrating the local product matches the originator. #### Stage 4: GMP build and qualification The local line is built or fitted out and qualified through installation, operational and performance qualification, often using modular and single-use equipment to compress the timeline. #### Stage 5: Inspection and approval The local site undergoes FDA, EMA or NMPA pre-approval inspection and is named in the market authorisation, which is the legal step that converts local build into market access. #### Stage 6: Commercial supply The site produces and releases commercial product for the target market under the access agreement, with ongoing GMP compliance and lifecycle change control maintaining the access qualification.